Health Canada has approved the enzyme replacement therapy Elfabrio (pegunigalsidase alfa) to treat adults with Fabry disease. “With…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Chiesi Global Rare Diseases and Protalix Biotherapeutics are asking a committee of the European Medicines Agency (EMA) to…
Enzyme replacement therapy (ERT) may help limit damage to blood vessels in the kidneys of people with Fabry…
Treatment with the experimental gene therapy AMT-191 led to increases in levels of the enzyme whose deficit causes…
Looking at blood vessels in the eye in people with Fabry disease may give clinicians new insights into problems…
Fatty deposits called myeloid bodies in urine may help diagnose Fabry disease and monitor how people with Fabry are…
Fabry disease patients showed improvements in kidney function in the year following a single dose of gene therapy…
Levels of certain molecules in the blood may help track disease activity and kidney damage in Fabry disease, a…
For Fabry Awareness Month this April, the Fabry International Network, or FIN — an alliance of 61 patient organizations…
People with different lysosomal storage diseases have varying beliefs about prescribed medicines, which reflect their current medical needs, a study…